Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Prostate Cancer

Free Subscription 03.12.2018 1 BJU Int 1 BMC Cancer 1 BMC Urol 1 Br J Cancer 1 Cancer Lett 1 Clin Imaging 11 Eur Urol 1 Int J Cancer 1 Int J Oncol 1 Int J Urol 1 J Magn Reson Imaging 1 Lancet Oncol 2 Nat Rev Urol 1 Oncogene 1 Oncol Rep 1 Oncology (Williston Park) 2 PLoS One 5 Prostate 1 Urol Int 2 Urology

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

BJU Int

1. GNANAPRAGASAM V, Barrett T, Massie C, Pacey S, et al
   Using prognosis to guide early detection and treatment selection in non-metastatic prostate cancer.
   BJU Int. 2018 Nov 30. doi: 10.1111/bju.14637.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

2. GHOSHAL A, Garmo H, Hammar N, Jungner I, et al
   Can pre-diagnostic serum levels of sodium and potassium predict prostate cancer survival?
   BMC Cancer. 2018;18:1169.
   PubMed     Text format     Abstract available
   
   

   
   BMC Urol

3. ZAKARIA AS, Dragomir A, Brimo F, Kassouf W, et al
   Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening.
   BMC Urol. 2018;18:69.
   PubMed     Text format     Abstract available
   
   

   
   Br J Cancer

4. DUTTO L, Ahmad A, Urbanova K, Wagner C, et al
   Development and validation of a novel risk score for the detection of insignificant prostate cancer in unscreened patient cohorts.
   Br J Cancer. 2018 Nov 27. pii: 10.1038/s41416-018-0316.
   PubMed     Text format     Abstract available
   
   

   
   Cancer Lett

5. CHENG H, Li X, Wang C, Chen Y, et al
   Inhibition of tankyrase by a novel small molecule significantly attenuates prostate cancer cell proliferation.
   Cancer Lett. 2018 Nov 22. pii: S0304-3835(18)30677.
   PubMed     Text format     Abstract available
   
   

   
   Clin Imaging

6. MEERMEIER NP, Turner KR, Foster BR, Varallyay C, et al
   Dominant intraprostatic cancer confirmed by direct MRI-guided biopsy: Concordance with histopathological findings.
   Clin Imaging. 2018;51:273-278.
   PubMed     Text format     Abstract available
   
   

   
   Eur Urol

7. MATEO J, Carles J
   Towards a New Classification for Metastatic Prostate Cancer.
   Eur Urol. 2018 Nov 19. pii: S0302-2838(18)30862.
   PubMed     Text format    
   
   
8. MAHON KL, Qu W, Lin HM, Spielman C, et al
   Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
   Eur Urol. 2018 Nov 19. pii: S0302-2838(18)30855.
   PubMed     Text format     Abstract available
   
   
9. TILKI D, Evans CP
   Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial.
   Eur Urol. 2018 Nov 19. pii: S0302-2838(18)30868.
   PubMed     Text format    
   
   
10. BOEVE LMS, Verhagen PCMS, Vis AN
    Reply to Ashwin Shinde, Richard Li, Arya Amini, and Scott Glaser's Letter to the Editor re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Th
    Eur Urol. 2018 Nov 21. pii: S0302-2838(18)30864.
    PubMed     Text format    
    
    
11. CIMADAMORE A, Scarpelli M, Santoni M, Cheng L, et al
    Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. J Vas
    Eur Urol. 2018 Nov 21. pii: S0302-2838(18)30895.
    PubMed     Text format    
    
    
12. HECK MM, Tauber R, Schwaiger S, Retz M, et al
    Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with (177)Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2018 Nov 22. pii: S0302-2838(18)30873.
    PubMed     Text format     Abstract available
    
    
13. LAM TBL, MacLennan S, Plass K, Willemse PM, et al
    Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer.
    Eur Urol. 2018 Nov 22. pii: S0302-2838(18)30866.
    PubMed     Text format    
    
    
14. ZAORSKY NG, Spratt DE, Blanchard P
    Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol
    Eur Urol. 2018 Nov 22. pii: S0302-2838(18)30882.
    PubMed     Text format    
    
    
15. GARCIA-PERDOMO HA
    Re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primar
    Eur Urol. 2018 Nov 23. pii: S0302-2838(18)30929.
    PubMed     Text format    
    
    
16. ROOBOL MJ
    Active Surveillance for Low-risk Prostate Cancer: Will it Become Obsolete?
    Eur Urol. 2018 Oct 25. pii: S0302-2838(18)30809.
    PubMed     Text format    
    
    
17. BECKMANN K, Garmo H, Adolfsson J, Bosco C, et al
    Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Eur Urol. 2018 Nov 26. pii: S0302-2838(18)30879.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

18. KOCHER S, Beyer B, Lange T, Nordquist L, et al
    A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer.
    Int J Cancer. 2018 Nov 26. doi: 10.1002/ijc.32018.
    PubMed     Text format     Abstract available
    
    

    
    Int J Oncol

19. ZHENG XM, Zhang P, Liu MH, Chen P, et al
    MicroRNA-30e inhibits adhesion, migration, invasion and cell cycle progression of prostate cancer cells via inhibition of the activation of the MAPK signaling pathway by downregulating CHRM3.
    Int J Oncol. 2018 Nov 26. doi: 10.3892/ijo.2018.4647.
    PubMed     Text format     Abstract available
    
    

    
    Int J Urol

20. INOUE Y, Ushijima S, Shiraishi T, Fujihara A, et al
    Biochemical and magnetic resonance image response in targeted focal cryotherapy to ablate targeted biopsy-proven index lesion of prostate cancer.
    Int J Urol. 2018 Nov 28. doi: 10.1111/iju.13857.
    PubMed     Text format    
    
    

    
    J Magn Reson Imaging

21. YOON YI, Ha SW, Lee HJ
    An ultrasound-responsive dual-modal US/T1 -MRI contrast agent for potential diagnosis of prostate cancer.
    J Magn Reson Imaging. 2018;48:1610-1616.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Oncol

22. CECCHINI M, Walther Z, Sklar JL, Bindra RS, et al
    Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes.
    Lancet Oncol. 2018;19:23-24.
    PubMed     Text format    
    
    

    
    Nat Rev Urol

23. RESCIGNO P, de Bono JS
    Immunotherapy for lethal prostate cancer.
    Nat Rev Urol. 2018 Nov 22. pii: 10.1038/s41585-018-0121.
    PubMed     Text format    
    
    
24. VAN DER TOOM EE, Axelrod HD, de la Rosette JJ, de Reijke TM, et al
    Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.
    Nat Rev Urol. 2018 Nov 27. pii: 10.1038/s41585-018-0119.
    PubMed     Text format     Abstract available
    
    

    
    Oncogene

25. WENG CC, Ding PY, Liu YH, Hawse JR, et al
    Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis.
    Oncogene. 2018 Nov 22. pii: 10.1038/s41388-018-0575.
    PubMed     Text format     Abstract available
    
    

    
    Oncol Rep

26. KAWAN MA, Kyrou I, Ramanjaneya M, Williams K, et al
    Involvement of the glutamine RFamide peptide and its cognate receptor GPR103 in prostate cancer.
    Oncol Rep. 2018 Nov 27. doi: 10.3892/or.2018.6893.
    PubMed     Text format     Abstract available
    
    

    
    Oncology (Williston Park)

27. KESSLER ER
    Management of Metastatic Prostate Cancer in Frail/Elderly Patients.
    Oncology (Williston Park). 2018;32:570-3.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

28. VARNAVA M, Sumida I, Mizuno H, Shiomi H, et al
    A new plan quality objective function for determining optimal collimator combinations in prostate cancer treatment with stereotactic body radiation therapy using CyberKnife.
    PLoS One. 2018;13:e0208086.
    PubMed     Text format     Abstract available
    
    
29. CHIU TD, Arai TJ, Campbell Iii J, Jiang SB, et al
    MR-CBCT image-guided system for radiotherapy of orthotopic rat prostate tumors.
    PLoS One. 2018;13:e0198065.
    PubMed     Text format     Abstract available
    
    

    
    Prostate

30. PAZIEWSKA A, Mikula M, Dabrowska M, Kulecka M, et al
    Candidate diagnostic miRNAs that can detect cancer in prostate biopsy.
    Prostate. 2018;78:178-185.
    PubMed     Text format     Abstract available
    
    
31. COHEN M, Amir S, Golan M, Ben-Neriah Y, et al
    beta-TrCP upregulates HIF-1 in prostate cancer cells.
    Prostate. 2018 Nov 28. doi: 10.1002/pros.23746.
    PubMed     Text format     Abstract available
    
    
32. KRUEGER TE, Thorek DLJ, Meeker AK, Isaacs JT, et al
    Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?
    Prostate. 2018 Nov 28. doi: 10.1002/pros.23738.
    PubMed     Text format     Abstract available
    
    
33. MAJERA D, Skrott Z, Bouchal J, Bartkova J, et al
    Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram.
    Prostate. 2018 Nov 29. doi: 10.1002/pros.23741.
    PubMed     Text format     Abstract available
    
    
34. ERLANDSSON A, Carlsson J, Lundholm M, Falt A, et al
    M2 macrophages and regulatory T cells in lethal prostate cancer.
    Prostate. 2018 Nov 30. doi: 10.1002/pros.23742.
    PubMed     Text format     Abstract available
    
    

    
    Urol Int

35. LEYH-BANNURAH SR, Zaffuto E, Dell'Oglio P, Tian Z, et al
    Prediction of Complications in Radical Prostatectomy Prostate Cancer Patients: Simulated Annealing versus Co-Morbidity Indexes.
    Urol Int. 2018 Nov 27:1-9. doi: 10.1159/000495071.
    PubMed     Text format     Abstract available
    
    

    
    Urology

36. MANNING TG, Cheung E, Perera M, Christidis D, et al
    Atypical Small Acinar Proliferation and High Grade Prostatic Intraepithelial Neoplasia in the Era of Multi-Parametric MRI: a Contemporary Review.
    Urology. 2017 Apr 21. pii: S0090-4295(17)30388.
    PubMed     Text format     Abstract available
    
    
37. CHEN J, Wang ZJ, Zhang KL, Xu YJ, et al
    Selective castration-resistant prostate cancer photothermal ablation with CuS nanoplates.
    Urology. 2018 Nov 21. pii: S0090-4295(18)31215.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: